| TL;DR The Wegovy pill (oral semaglutide 25 mg) received FDA approval in December 2025 and launched in the US in January 2026, but it has not yet been approved by the MHRA for use in the UK, with a decision broadly expected by late 2026. The Phase III OASIS 4 clinical trial showed a mean weight loss of 16.6% over 64 weeks among fully adherent participants, with one in three achieving 20% or more weight loss. The pill contains the same active ingredient as the weekly injection but is taken once daily. |
If you have been following developments in weight loss medicine over the past year, you will already know that semaglutide has completely reshaped how obesity is understood and treated. For most UK patients, semaglutide has meant weekly injections, either through the Wegovy pen or Ozempic, both manufactured by Novo Nordisk.
But 2026 marks a genuine turning point. The pharmaceutical company has successfully brought an oral tablet version of Wegovy. This guide talks about it and what you should consider doing in the meantime if you are looking for a clinically proven weight loss treatment right now.
What Is the Wegovy Pill and How Is It Different from the Injection?
The Wegovy pill is an oral tablet version of semaglutide, the same active ingredient found in the weekly Wegovy injection. It was developed by Novo Nordisk specifically for the management of obesity and overweight in adults. While the injectable form has been licensed in the UK since 2022 and delivers semaglutide via a subcutaneous pen injected once weekly, the oral tablet is taken once daily by mouth.
Both forms work through the same underlying mechanism. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring hormone released by the gut after eating. It signals the brain to;
- Reduce hunger
- Slows the rate at which food leaves the stomach
- Helps regulate blood sugar levels.
By mimicking this hormone continuously, semaglutide helps people consume fewer calories without experiencing the kind of intense hunger that makes conventional dieting so difficult to sustain.
The Technology Behind Oral Semaglutide
The challenge with oral semaglutide is that proteins like GLP-1 are normally broken down in the digestive tract before they can be absorbed into the bloodstream. Novo Nordisk overcame this barrier using a technology called the Salcaprozate Sodium (SNAC) absorption enhancer. SNAC temporarily increases the permeability of cells in the stomach lining, allowing semaglutide to be absorbed locally.
Because of this absorption mechanism, the pill must be taken very precisely. It should be swallowed whole with no more than 120 ml of plain water on an empty stomach, immediately after waking. The patient must then wait at least 30 minutes before consuming any food, drink, or other medication. Taking it with coffee, juice, or food significantly reduces how much semaglutide the body actually absorbs.
| Feature | Wegovy Injection (2.4 mg) | Wegovy Pill (25 mg) |
| Active ingredient | Semaglutide | Semaglutide |
| Administration | Subcutaneous injection | Oral tablet |
| Frequency | Once weekly | Once daily |
| Mean weight loss (trial) | ~15% over 68 weeks (STEP 1) | 16.6% over 64 weeks (OASIS 4) |
| UK licensed status | Yes (MHRA approved) | No (under review) |
| UK availability | Private and specialist NHS | Not yet available |
| Food restrictions | None | 30-min fast required after taking |
Wegovy Tablet UK 2026: Where Does the MHRA Stand?
As of April 2026, the Wegovy oral tablet has not been approved for use in the United Kingdom. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for evaluating the safety, quality, and efficacy of all medicines before they can be prescribed to patients. Following the UK’s departure from the European Union, the MHRA now operates its own independent review process rather than automatically following the European Medicines Agency (EMA).
Novo Nordisk submitted oral semaglutide for review to the EMA and other regulatory authorities, including the MHRA, during the second half of 2025. Following MHRA approval, the National Institute for Health and Care Excellence (NICE) would then need to conduct its own health technology appraisal before the pill could be considered for NHS provision. That process typically takes several additional months.
OASIS 4 Trial Semaglutide Results
The most relevant study for UK patients evaluating the pill is the OASIS 4 trial, a 64-week randomised study of once-daily oral semaglutide 25 mg in 307 adults with obesity or overweight with at least one weight-related comorbidity.
These are clinically significant results. To put them in context, a person weighing 100 kg who adhered fully to treatment would, on average, lose approximately 16.6 kg over 64 weeks. One third of participants lost at least 20 kg in every 100 kg of starting weight. The placebo group, by comparison, lost just 2.7% on average.
Safety Profile in the OASIS 4 Trial
The safety profile of the Wegovy pill is consistent with other semaglutide treatments.
Common Side Effects
- Nausea (46.6%)
- Vomiting (30.9%)
- Digestive discomfort
These are usually:
- Mild to moderate
- Temporary during dose escalation
Important Safety Warning
Semaglutide carries a class warning regarding thyroid tumours.
It should not be used in people with:
- Medullary thyroid cancer history
- MEN 2 syndrome
Always consult a qualified prescriber before starting treatment.
Wegovy Pill UK 2026: Regulatory Status
As of April 2026, the Wegovy pill is:
- Approved in the United States
- Under review in the UK
The UK regulatory process involves:
- MHRA approval (safety and efficacy review)
- NICE evaluation (cost-effectiveness and NHS eligibility)
Expected Timeline
- MHRA decision: Late 2026 (estimated)
- NHS availability: Likely 2027 or later
This means patients looking for treatment today will need to consider available alternatives.
What Happens When You Stop Taking Wegovy Pill?
This is one of the most important considerations.
Semaglutide does not permanently change metabolism. If treatment stops:
- Appetite returns
- Weight regain is common
Long-Term Strategy
Successful patients typically:
- Continue treatment under supervision
or - Transition to strong lifestyle maintenance
Will the Wegovy Tablet Be Available on the NHS?
Unlikely in the short term.
Currently, Wegovy injections are only available on the NHS if:
- BMI ≥35
- At least one weight-related condition
- Through specialist services
Even after approval, the pill will require a separate NICE review, which can take 6–18 months.
Who Will Be Eligible in the UK?
Based on current frameworks, eligibility will likely include:
- BMI ≥30
- BMI ≥27 with conditions such as:
- Type 2 diabetes
- Hypertension
- Sleep apnoea
Who Should Not Use It
- Pregnant or breastfeeding individuals
- History of thyroid cancer
- Severe pancreatitis
Final Thoughts
The Wegovy pill marks a significant step forward in weight-loss treatment, offering a convenient, needle-free option that could expand access for many patients in the future. However, for those in the UK, it is not yet available; regulatory approval is still pending, and widespread access is unlikely before late 2026 or beyond.
At Batley Pharmacy, you can access clinically approved weight loss injections, personalised treatment plans, and ongoing pharmacist support tailored to your needs.
FAQs
When will the Wegovy pill be available in the UK?
A decision is expected from the MHRA in late 2026. NHS availability would likely follow in 2027 or later.
How effective is the Wegovy pill?
Clinical trials show an average of 16.6% weight loss over 64 weeks, with some individuals achieving 20% or more.
Is the pill better than the injection?
Effectiveness appears similar, but the pill requires strict dosing conditions, while injections are more convenient.
How much will it cost in the UK?
Estimated pricing is £150–£300 per month, similar to current injection treatments.
Can I switch from injection to pill?
Yes, this may be possible under medical supervision once the pill is approved in the UK.